The company reported a loss on foreign currency exchange and net interest expense. Cash and cash equivalents decreased from the beginning to the end of the first quarter. The company was recently granted FDA approval for the investigational device exemption supplement for additional clinical trials for its dermaPACE.
More Articles on Orthopedic Devices:
14 Spine Devices Receive FDA 510(k) Clearance in April
MiMex Group Q1 Net Sales at $37M
US Spinal Implant Market to Reach $7B by 2018, Driven by Motion Preservation
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.